Hyperthermic Oncology from Bench to Bedside pp 257-259 | Cite as
Combination by Hyperthermia and Chemotherapy: Esophageal Cancer
Chapter
First Online:
Abstract
Chemotherapy has an important role in the treatment of esophageal cancer; e.g., neoadjuvant chemotherapy and concurrent chemoradiotherapy are used for locally advanced cases and for the systemic treatment of recurrent or metastatic disease. Local or regional hyperthermia can enhance the efficacy of systemic chemotherapy in specific areas. In this chapter, hyperthermic chemosensitization is outlined, and the clinical results of chemotherapy with hyperthermia used particularly for the treatment of esophageal cancer are presented.
Keywords
Hyperthermia Chemotherapy Esophageal cancerReferences
- 1.Mohamed F, Marchettini P, Stuart OA, Urano M, Sugarbaker PH. Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia. Ann Surg Oncol. 2003;10(4):463–8.CrossRefPubMedGoogle Scholar
- 2.Jones EL, Samulski TV, Vujaskovic Z, Leonard RP, Dewhirst MW. Hyperthermia. Principles and practice of radiation oncology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2003.Google Scholar
- 3.Hettinga JV, Konings AW, Kampinga HH. Reduction of cellular cisplatin resistance by hyperthermia – a review. Int J Hyperthermia. 1997;13(5):439–57.CrossRefPubMedGoogle Scholar
- 4.Da Silva VF, Feeley M, Raaphorst GP. Hyperthermic potentiation of BCNU toxicity in BCNU-resistant human glioma cells. J Neurooncol. 1991;11(1):37–41.CrossRefPubMedGoogle Scholar
- 5.Ohguri T, Imada H, Narisada H, Yahara K, Morioka T, Nakano K, et al. Systemic chemotherapy using paclitaxel and carboplatin plus regional hyperthermia and hyperbaric oxygen treatment for non-small cell lung cancer with multiple pulmonary metastases: preliminary results. Int J Hyperthermia. 2009;25(2):160–7. doi:910057552 [pii] 10.1080/02656730802610357.CrossRefPubMedGoogle Scholar
- 6.Ohguri T, Imada T, Korogi Y, Narisada H. Clinical results of systemic chemotherapy combined with regional hyperthermia. Thermal Med. 2007;23(2):49–61.CrossRefGoogle Scholar
- 7.Koshy M, Esiashvilli N, Landry JC, Thomas Jr CR, Matthews RH. Multiple management modalities in esophageal cancer: combined modality management approaches. Oncologist. 2004;9(2):147–59.CrossRefPubMedGoogle Scholar
- 8.Roussel A, Haegele P, Paillot B, Gignoux M, Marinus A, Sahmoud T, et al. Results of the EORTC-GTCCG phase III trial of irradiation vs irradiation and CDDP in inoperable esophageal cancer. Proc Am Soc Clin Oncol. 1994;13:199.Google Scholar
- 9.Yano T, Muto M, Hattori S, Minashi K, Onozawa M, Nihei K, et al. Long-term results of salvage endoscopic mucosal resection in patients with local failure after definitive chemoradiotherapy for esophageal squamous cell carcinoma. Endoscopy. 2008;40(9):717–21. doi: 10.1055/s-2008-1077480.CrossRefPubMedGoogle Scholar
- 10.Swisher SG, Wynn P, Putnam JB, Mosheim MB, Correa AM, Komaki RR, et al. Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg. 2002;123(1):175–83. doi:S0022522302495116 [pii].CrossRefPubMedGoogle Scholar
- 11.Nishimura S, Saeki H, Nakanoko T, Kasagi Y, Tsuda Y, Zaitsu Y, et al. Hyperthermia combined with chemotherapy for patients with residual or recurrent oesophageal cancer after definitive chemoradiotherapy. Anticancer Res. 2015;35(4):2299–303.PubMedGoogle Scholar
- 12.Issels RD, Lindner LH, Verweij J, Wust P, Reichardt P, Schem BC, et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol. 2010;11(6):561–70. doi:S1470-2045(10)70071-1 [pii] 10.1016/S1470-2045(10)70071-1.CrossRefPubMedPubMedCentralGoogle Scholar
Copyright information
© Springer Science+Business Media Singapore 2016